U.S. markets closed
  • S&P Futures

    3,817.50
    -3.75 (-0.10%)
     
  • Dow Futures

    30,978.00
    -21.00 (-0.07%)
     
  • Nasdaq Futures

    11,678.50
    -12.50 (-0.11%)
     
  • Russell 2000 Futures

    1,719.80
    -1.60 (-0.09%)
     
  • Crude Oil

    109.60
    -0.18 (-0.16%)
     
  • Gold

    1,819.90
    +2.40 (+0.13%)
     
  • Silver

    20.66
    -0.01 (-0.06%)
     
  • EUR/USD

    1.0444
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    3.0930
    -0.1130 (-3.52%)
     
  • Vix

    28.16
    -0.20 (-0.71%)
     
  • GBP/USD

    1.2123
    +0.0001 (+0.01%)
     
  • USD/JPY

    136.7330
    +0.1880 (+0.14%)
     
  • BTC-USD

    20,116.50
    -191.19 (-0.94%)
     
  • CMC Crypto 200

    432.99
    -6.67 (-1.52%)
     
  • FTSE 100

    7,312.32
    -11.09 (-0.15%)
     
  • Nikkei 225

    26,644.05
    -160.55 (-0.60%)
     

Champions Oncology to Announce Third Quarter Financial Results on Tuesday, March 15, 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the third quarter ended January 31, 2022, on Tuesday, March 15, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 692343. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 44896, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a data-driven research organization, with headquarters in the United States, that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration.

For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/692638/Champions-Oncology-to-Announce-Third-Quarter-Financial-Results-on-Tuesday-March-15-2022